GLPwatch

Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue.

J Mol Endocrinol · 2022

Last updated 2026-05-28

In mice fed a high-fat diet, the diabetes drug liraglutide (150 µg/kg daily) reversed reductions in two proteins, TCF7L2 and β-catenin, in fat tissue. The effect required a working GLP-1 receptor, which was found in the fat tissue’s stromal vascular fraction. In lab dishes, liraglutide directly raised cAMP levels and increased phosphorylation of CREB and β-catenin in these fat cells.

AI summary of the abstract below.

JournalJ Mol Endocrinol, 2022
Citations8
Relative citation ratio0.64
NIH percentile36
Molecules liraglutide

Abstract

Although canonical Wnt signaling pathway activation was shown to negatively regulate adipogenesis, recent investigations suggest that Wnt pathway effectors TCF7L2 and β-catenin (β-cat) in adipose tissues are also involved in energy homeostasis during adulthood. In assessing the metabolic beneficial effect of GLP-1-based diabetes drugs in high-fat diet (HFD)-challenged mice, we observed that liraglutide treatment affected the expression of a battery of adipose tissue-specific genes, including those that encode adiponectin and leptin, mainly in epididymal white adipose tissue (eWAT). Fourteen-week HFD challenge repressed TCF7L2 and β-cat S675 phosphorylation in eWAT, while such repression was reversed by liraglutide treatment (150 µg/kg body weight daily) during weeks 10-14. In Glp1r-/-mice, liraglutide failed in stimulating TCF7L2 or β-cat in eWAT. We detected Glp1r expression in mouse eWAT and its level is enriched in its stromal vascular fraction (SVF). Mouse eWAT-SVF showed reduced expression of Tcf7l2 and its Tcf7l2 level could not be stimulated by liraglutide treatment; while following adipogenic differentiation, rat eWAT-SVF showed elevated Tcf7l2 expression. Direct in vitro liraglutide treatment in eWAT-SVF stimulated CREB S133, β-cat S675 phosphorylation, and cellular cAMP level. Thus, cAMP/β-cat signaling cascade can be stimulated by liraglutide in eWAT via GLP-1R expressed in eWAT-SVF.

Verbatim abstract via PubMed 35552259 ↗

Related research